Asthma is a long-term chronic condition that affects an estimated 339 million people worldwide.

Despite advances in treatment options, some people no longer respond to or have a reduced response to treatment. As such, alternative, more personalised treatment options are needed.

The investigational study drug, Atuliflapon, has been developed to reduce the number of substances in the body called leukotrienes that can cause our airways to become inflamed. Airways are the pipes we use to breathe, and they become narrower during inflammation.

Treating and preventing diseases based on a person’s unique biologic make-up, environment and lifestyle is known as precision medicine. Precision medicine aims to provide an alternative to the common ‘one-size-fits-all’ approach of current prescription medicine, by instead identifying the right treatment, for the right person, at the right time.

The FLASH Study team are interested in understanding whether a substance in the body, called a biomarker, can help identify people with moderate-to-severe asthma who may benefit the most from treatment with Atuliflapon.

All medicines, whether approved or investigational, may cause unwanted effects. The potential and known side effects of the investigational study drug are listed in the Informed Consent Form (you will be given the Informed Consent Form before you decide to join the study). Some of the more common side effects that have been reported following use of Atuliflapon include dizziness, anaemia and cough. It is possible that you may experience similar side effects during your participation in the FLASH Study. The study doctor will discuss potential side effects with you.

If you do experience any discomfort during the study, you can contact the study doctor at any time to discuss the best course of action. Throughout the study, your health will be monitored continuously. Your participation in the study will be stopped if you or the study doctor have any concerns.

Joining the FLASH Study is voluntary, and you can leave the study at any time and for any reason; this decision will not affect any future medical care that you may receive. You may also be removed from the study if the study doctor decides that continuing is not in your best interest. If a decision to leave is made by you or the study doctor, you will be asked to return to the study centre to undergo final tests and assessments.

We encourage you to inform your regular doctor that you are taking part in a clinical research study; your doctor may wish to contact the study doctor (with your permission) to request additional information.